MicroPort’s Joint Venture with Robocath


Dentons assisted MicroPort in the deal.

MicroPort completed the negotiation of an agreement with Robocath, a French company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, for the creation of a joint venture with its MicroPort MedBot (Shanghai) Co. Ltd subsidiary.

This strategic partnership will enable Robocath the commercialization of its first robotic-assisted platform – R-One™ – in China, today the world’s biggest market in interventional cardiology. The expansion to the Chinese market will be facilitated by local manufacturing of consumables and robotic assembly to ensure optimal distribution of Robocath products. The testing, clinical and regulatory activities required to receive National Medical Products Administration (NMPA) approval for R-One™ will begin immediately.

As agreed in the terms of the investment announced in April 2020, both companies will also carry out research and development activities related to the next long-distance generation of remote control over 5G network technologies and will develop artificial intelligence algorithms to be used with robotic-assisted platforms.

MicroPort is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally.

Dentons advised MicroPort with a team led by Partner Anne-Laure Marcerou and associates Pierre-Marie Gallo and Guillaume Béraud from the Corporate Life Sciences team in Paris.

Involved fees earner: Guillaume Beraud – Dentons; Pierre-Marie Gallo – Dentons; Anne-Laure Marcerou – Dentons;

Law Firms: Dentons;

Clients: MicroPort Scientific Corporation;